Sept 6 (Reuters) – Danaher Corp said on Tuesday it
would buy molecular diagnostics company Cepheid in a
deal valued at $4 billion, including debt, to strengthen its
diagnostics business.
The post UPDATE 2-Danaher to buy Cepheid in $4 bln deal to expand in diagnostics appeared first on NASDAQ.